12:00 AM
 | 
Dec 23, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Sofosbuvir: Phase III data

Gilead reported top-line data from 440 treatment-experienced patients with chronic HCV genotype 1 infection in the open-label, U.S. Phase III ION-2 trial evaluating a once-daily, oral fixed-dose combination of 400 mg sofosbuvir plus 90 mg ledipasvir with or without ribavirin for 12 or 24 weeks. SVR12 rates were 96.4% for sofosbuvir plus ledipasvir with ribavirin for 12 weeks (n=111), 93.6% for sofosbuvir plus ledipasvir without ribavirin for 12 weeks (n=109), 99.1% for sofosbuvir plus ledipasvir with ribavirin for 24 weeks (n=111) and 99.1% for sofosbuvir plus ledipasvir without ribavirin for 24...

Read the full 435 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >